Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 15/20 | 0.72 |
| ▸ | MAPT | P10636 | 9/20 | 0.53 |
| ▸ | NPC1 | O15118 | 5/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9772272 | 0.85 | ALDH1A1 (0.81) | ALDH1A1MAPTNPC1RAB9AMEN1 | |
| SCHEMBL4874761 | 0.81 | ALDH1A1 (0.80) | ALDH1A1MAPTNPC1RAB9AMEN1 | |
| SCHEMBL2558341 | 0.76 | ALDH1A1 (0.57) | ALDH1A1MAPTRAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL10642418 | 0.76 | ALDH1A1 (0.67) | ALDH1A1MAPTNPC1RAB9AMEN1 | |
| SCHEMBL9401952 | 0.76 | ALDH1A1 (0.57) | ALDH1A1MAPTNPC1RAB9AMEN1 | |
| SCHEMBL2551654 | 0.75 | ALDH1A1 (0.55) | ALDH1A1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL13568567 | 0.74 | ALDH1A1 (0.56) | ALDH1A1MAPTNPC1RAB9AMEN1 | |
| SCHEMBL2558523 | 0.73 | ALDH1A1 (0.54) | ALDH1A1RAB9AKDM4ESMN1; SMN2HTT | |
| SCHEMBL9772389 | 0.73 | ALDH1A1 (0.54) | ALDH1A1MAPTNPC1RAB9AMEN1 | |
| SCHEMBL2558791 | 0.73 | ALDH1A1 (0.63) | ALDH1A1MAPTKDM4ESMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023135536-A1 | CORALLINE CERAMIC MATERIAL, SENSOR AND METHOD FOR OBTAINING SAID MATERIAL | UNIVERSIDAD DE LOS ANDES (CO) | 2023-07-20 | — | — | WO | claimed |
| WO-2026044253-A1 | GENETICALLY ENCODED FLUORESCENT SENSORS FOR VISUALIZING POLYAMINE LEVELS, UPTAKE, AND DISTRIBUTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-26 | — | — | WO | disclosed |
| US-12504393-B2 | Method and system for determining the progesterone-associated physiological state of lactating cows | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2025-12-23 | — | — | US | disclosed |
| US-20250367321-A1 | COMPOSITIONS AND METHODS INVOLVING ADGRG6 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4593953-A1 | INHIBITION OF LUTEINIZING HORMONE (LH) ACTION AS TREATMENT OF PERIMENOPAUSAL AND POSTMENOPAUSAL SYMPTOMS AND COMPLICATIONS | Rigshospitalet (DK) | 2025-08-06 | — | — | EP | disclosed |
| US-20250199007-A1 | EXTRACELLULAR VESICLE BIOMARKERS FOR BLADDER CANCER | TYMORA ANALYTICAL OPERATIONS, LLC (US) | 2025-06-19 | — | — | US | disclosed |
| US-20250186520-A1 | ONCOLYTIC VIRUS COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | HOPE CITY (US) | 2025-06-12 | — | — | US | disclosed |
| CN-120030359-A | Timing sequence prediction method and system based on visual algorithm | 西北农林科技大学 | 2025-05-23 | — | — | CN | disclosed |
| US-20250064056-A1 | CONTACT PHEROMONE-CONTAINING COMPOSITION FOR CONTROLLING THRIPS, KIT COMPOSITION FOR CONTROLLING THRIPS, AND METHOD OF CONTROLLING THRIPS BY USING SAME | ANDONG NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2025-02-27 | — | — | US | disclosed |
| EP-2648500-B1 | PHYTOPHTHORA RESISTANCE IN SWEET PEPPERS | HM CLAUSE (FR) | 2025-01-29 | — | — | EP | disclosed |
| US-20220362260-A1 | METHODS OF TREATING LIPEDEMA INCLUDING AKR1C1 AS A THERAPEUTIC TARGET | MAGI EUREGIO SCS (IT) | 2022-11-17 | — | — | US | disclosed |
| US-20220339134-A1 | VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS, ELOVANOID HYDROXYLATED DERIVATIVES, AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-10-27 | — | — | US | disclosed |
| EP-4025201-A1 | VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS, ELOVANOID HYDROXYLATED DERIVATIVES, AND METHODS OF USE | Board of Supervisors of Louisiana State University and Agricultural and Mechanical College (US) | 2022-07-13 | — | — | EP | disclosed |
| WO-2022140418-A1 | VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS, ELOVANOID HYDROXYLATED DERIVATIVES, AND METHODS OF USE | THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2022-06-30 | — | — | WO | disclosed |
| CN-114650814-A | Very long chain polyunsaturated fatty acid, elongin-like hydroxylated derivatives and methods of use | 路易斯安娜州立大学监测委员会，农业和机械学院 | 2022-06-21 | — | — | CN | disclosed |
| WO-2022093857-A1 | ONCOLYTIC VIRUS COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | CITY OF HOPE (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022051819-A1 | APPARATUS AND PROCESS FOR ELECTROMAGNETIC IMAGING | EMvision Medical Devices Ltd (AU) | 2022-03-17 | — | — | WO | disclosed |
| EP-3713423-B1 | PROCEDURE FOR THE PRODUCTION OF A MULTIPLIER AND MODULATOR ADDITIVE OF THE RUMINAL MICROBIOTE | BIOPREMIX TECH LLC (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-113930416-A | Preparation method of biochar immobilized laccase based on compound modification of sodium hydroxide and ferroferric oxide crystals | 南开大学 | 2022-01-14 | — | — | CN | disclosed |
| US-20120308588-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120308588-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | ALDH1A1 2714/4885MAPT 527/4885NPC1 214/4885 |
| US-20220339134-A1 | VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS, ELOVANOID HYDROXYLATED DERIVATIVES, AND METHODS OF USE | ELOVL3, ELOVL1, ALOX5 | ALDH1A1 631/4885MAPT 4822/4885NPC1 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.